-
Press Release
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Press Release
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
-
Press Release
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
-
Story
Word on the Street: What is cell and gene therapy? -
Story
Bringing real change to people -
Story
An up-close look at cryo-electron microscopy -
Story
Reimagining protein sequencing -
Story
Embracing big data to understand complex diseases -
Story
Systematically exposing vulnerabilities of cancer cells -
Story
Minion challenges assumptions about the genome -
Story
Saving tumor suppressors from the shredder -
Story
Countering the genome reprogramming of cancer cells